Paula Isabel Burgos

Paula Isabel Burgos

Auto-generated profile, based on publicly available information

Paula Isabel Burgos

Pontificia Universidad Catolica de Chile, Santiago, Chile

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 April 2019 in Frontiers in Immunology
Verified
Journal Article
Open access
AHAndrés A. Herrada
Andrés A. Herrada
NENoelia Escobedo
Noelia Escobedo
MIMirentxu Iruretagoyena
Mirentxu Iruretagoyena
RVRodrigo A. Valenzuela
Rodrigo A. Valenzuela
PBPaula I. Burgos
Paula I. Burgos
CLCarolina Llanos
Carolina Llanos
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by the presence of autoantibodies against nuclear antigens, immune complex deposition and tissue damage in the kidneys, skin, heart and lung. Because of the pathogenic role of antinuclear antibodies and autoreactive T cells in SLE, extensive efforts have been made to demonstrate how B cells act as antibody-producing or as antigen-presenting cells that can prime autoreactive T cell activation. With the discovery of new innate immune cells and inflammatory mediators, innate immunity is emerging as a key player in disease pathologies. Recent work over the last decade has highlighted the importance of innate immune cells and molecules in promoting and potentiating SLE. In this review, we discuss recent evidence of the involvement of different innate immune cells and pathways in the pathogenesis of SLE. We also discuss new therapeutics targets directed against innate immune components as potential novel therapies in SLE.

29 September 2015 in Frontiers in Immunology
Verified
Journal Article
Open access
GAGabriel Arellano
Gabriel Arellano
POPayton A. Ottum
Payton A. Ottum
LRLilian I. Reyes
Lilian I. Reyes
PBPaula I. Burgos
Paula I. Burgos
RNRodrigo Naves
Rodrigo Naves
The role of interferon-γ (IFN-γ) in multiple sclerosis (MS) and its animal model experimental autoimmune encephalomyelitis (EAE) has remained as an enigmatic paradox for more than 30 years. Several studies attribute this cytokine a prominent proinflammatory and pathogenic function in these pathologies. However, accumulating evidence shows that IFN-γ also plays a protective role inducing regulatory cell activity and modulating the effector T cell response. Several innate and adaptive immune cells also develop opposite functions strongly associated with the production of IFN-γ in EAE. Even the suppressive activity of different types of regulatory cells is dependent on IFN-γ. Interestingly, recent data supports a stage-specific participation of IFN-γ in EAE providing a plausible explanation for previous conflicting results. In this review, we will summarize and discuss such literature, emphasizing the protective role of IFN-γ on immune cells. These findings are fundamental to understand the complex role of IFN-γ in the pathogenesis of these diseases and can provide basis for potential stage-specific therapy for MS targeting IFN-γ-signaling or IFN-γ-producing immune cells.

1 November 2018 in Annals of the Rheumatic Diseases
Verified
Journal Article
Open access
PDF file
BPBernardo A Pons-Estel
Bernardo A Pons-Estel
EBEloisa Bonfa
Eloisa Bonfa
ESEnrique R Soriano
Enrique R Soriano
MCMario H Cardiel
Mario H Cardiel
AIAriel Izcovich
Ariel Izcovich
GAGraciela S Alarcón
Graciela S Alarcón
Systemic lupus erythematosus (SLE), a complex and heterogeneous autoimmune disease, represents a significant challenge for both diagnosis and treatment. Patients with SLE in Latin America face special problems that should be considered when therapeutic guidelines are developed. The objective of the study is to develop clinical practice guidelines for Latin American patients with lupus. Two independent teams (rheumatologists with experience in lupus management and methodologists) had an initial meeting in Panama City, Panama, in April 2016. They selected a list of questions for the clinical problems most commonly seen in Latin American patients with SLE. These were addressed with the best available evidence and summarised in a standardised format following the Grading of Recommendations Assessment, Development and Evaluation approach. All preliminary findings were discussed in a second face-to-face meeting in Washington, DC, in November 2016. As a result, nine organ/system sections are presented with the main findings; an ‘overarching’ treatment approach was added. Special emphasis was made on regional implementation issues. Best pharmacologic options were examined for musculoskeletal, mucocutaneous, kidney, cardiac, pulmonary, neuropsychiatric, haematological manifestations and the antiphospholipid syndrome. The roles of main therapeutic options (ie, glucocorticoids, antimalarials, immunosuppressant agents, therapeutic plasma exchange, belimumab, rituximab, abatacept, low-dose aspirin and anticoagulants) were summarised in each section. In all cases, benefits and harms, certainty of the evidence, values and preferences, feasibility, acceptability and equity issues were considered to produce a recommendation with special focus on ethnic and socioeconomic aspects. Guidelines for Latin American patients with lupus have been developed and could be used in similar settings.

19 May 2009 in Rheumatology
Verified
Journal Article
Open access
PDF file
GPGuillermo J. Pons-Estel
Guillermo J. Pons-Estel
LGLuis A. González
Luis A. González
JZJie Zhang
Jie Zhang
PBPaula I. Burgos
Paula I. Burgos
JRJohn D. Reveille
John D. Reveille
GAGraciela S. Alarcón
Graciela S. Alarcón
Objective. To determine the features predictive of atherosclerotic cardiovascular damage in patients with SLE. Methods. SLE LUMINA (LUpus in MInorities: NAture vs nurture) patients (n = 637), aged ⩾16 years, disease duration ⩽5 years at baseline (T0), of African–American, Hispanic and Caucasian ethnicity were studied. Atherosclerotic cardiovascular damage was defined by the following items of the SLICC Damage Index (SDI) cardiovascular domain: angina or coronary artery by pass surgery, myocardial infarction and/or congestive heart failure; factors associated with its occurrence were examined by univariable and multivariable regression analyses. Results. Forty-three (6.8%) of 637 patients developed cardiovascular damage over a mean ± s.d. total disease duration of 6.6 ± 3.6 years. Nearly 90% of the patients were women with a mean ± s.d. age of 36.5 (12.6) years; all ethnic groups were represented. By multivariable analyses, after adjusting for the cardiovascular manifestations present, age [odds ratio (OR) = 1.06; 95% CI 1.03, 1.09], male gender (OR = 3.57; 95% CI 1.35, 9.09) SDI at baseline (OR = 1.28; 95% CI 1.09, 1.50) and CRP levels [highest tertile (OR = 2.63; 95% CI 1.17, 5.91)] were associated with the occurrence of cardiovascular damage, whereas the number of years of education was negatively associated with such outcome (OR = 0.85; 95% CI 0.74, 0.94). Conclusions. Our data suggest that atherosclerotic cardiovascular damage in SLE is multifactorial; traditional (age, gender) and disease-related factors (CRP levels, SDI at baseline) appear to be important contributors to such an occurrence. Tight control of the inflammatory process must be achieved to prevent it.

27 August 2009 in Arthritis Care & Research
Verified
Journal Article
Open access
PDF file
PBPaula I. Burgos
Paula I. Burgos
GAGraciela S. Alarcón
Graciela S. Alarcón
GMGerald McGwin
Gerald McGwin
KCKendra Q. Crews
Kendra Q. Crews
JRJohn D. Reveille
John D. Reveille
LVLuis M. Vilá
Luis M. Vilá
Objective: To determine the factors associated with increased levels of fatigue over the course of the disease in systemic lupus erythematosus (SLE) patients from LUpus in MInorities: NAture versus nurture, a longitudinal multiethnic cohort.Methods: Patients with SLE (according to the American College of Rheumatology revised and updated criteria) age ≥16 years with a disease duration ≤5 years at entry into the cohort, and of Hispanic (Texan or Puerto Rican), African American, or Caucasian ethnicity were studied. The association between socioeconomic/demographic characteristics, health behaviors, behavioral and psychological, functional and clinical characteristics, and fatigue was examined using generalized estimating equations to account for the longitudinal nature of the data.Results: A total of 515 patients (∼91% female) contributed 2,609 visits to these analyses. Of these patients, 93 (18.1%) were Texan‐Hispanic, 101 (19.6%) were Puerto Rican‐Hispanic, 169 (32.8%) were African Americans, and 152 (29.5%) were Caucasian. The mean ± SD patient age and followup time were 37.2 ± 12.6 years and 4.7 ± 3.2 years, respectively. Variables associated with increased levels of fatigue in the multivariable analyses were Caucasian ethnicity, the presence of constitutional symptoms (fever, weight loss), and higher levels of pain, abnormal illness‐related behaviors, and helplessness (P values between 0.0018 and <0.0001).Conclusion: The presence of pain, abnormal illness‐related behaviors, helplessness, and constitutional manifestations were associated with increased levels of fatigue. However, SLE‐specific measures, such as disease activity and damage, were not. Interventions aimed at decreasing fatigue need to take into account these findings.

27 August 2009 in Arthritis & Rheumatism
Verified
Journal Article
Open access
PDF file
PBPaula I. Burgos
Paula I. Burgos
EPElizabeth L. Perkins
Elizabeth L. Perkins
GPGuillermo J. Pons‐Estel
Guillermo J. Pons‐Estel
SKScott A. Kendrick
Scott A. Kendrick
JLJigna M. Liu
Jigna M. Liu
CKClifton E. Kew
Clifton E. Kew
Objective: To determine the risk factors for recurrent lupus nephritis, allograft loss, and survival among patients with systemic lupus erythematosus (SLE) undergoing kidney transplantation.Methods: The archival records of all kidney transplant recipients with a prior diagnosis of SLE (according to the American College of Rheumatology criteria) from June 1977 to June 2007 were reviewed. Patients who had died or lost the allograft within 90 days of engraftment were excluded. Time‐to‐event data were examined by univariable and multivariable Cox proportional hazards regression analyses.Results: Two hundred twenty of nearly 7,000 renal transplantations were performed in 202 SLE patients during the 30‐year interval. Of the 177 patients who met the criteria for study entry, the majority were women (80%) and African American (65%), the mean age was 35.6 years, and the mean disease duration was 11.2 years. Recurrent lupus nephritis was noted in 20 patients (11%), allograft loss in 69 patients (39%), and death in 36 patients (20%). African American ethnicity was found to be associated with a shorter time‐to‐event for recurrent lupus nephritis (hazard ratio [HR] 4.63, 95% confidence interval [95% CI] 1.29–16.65) and death (HR 2.47, 95% CI 0.91–6.71), although, with the latter, the association was not statistically significant. Recurrent lupus nephritis and chronic rejection of the kidney transplant were found to be risk factors for allograft loss (HR 2.48, 95% CI 1.09–5.60 and HR 2.72, 95% CI 1.55–4.78, respectively). In patients with recurrent lupus nephritis, the lesion in the engrafted kidney was predominantly mesangial, compared with a predominance of proliferative or membranous lesions in the native kidneys.Conclusion: African American ethnicity was independently associated with recurrent lupus nephritis. Allograft loss was associated with chronic transplant rejection and recurrence of lupus nephritis. Recurrent lupus nephritis is infrequent and relatively benign, without influence on a patient's survival.